MacPherson Edward Clouston 4

What Happened Edward Clouston MacPherson, a director of Mira Pharmaceuticals, was granted 50,000 stock options on June 12, 2026. The options were issued as an award (derivative grant) under the company’s 2022 Omnibus Incentive Plan. The reported exercise price is $0.94 per share; the Form 4 shows an acquisition value of $0 because this is an option grant, not a cash purchase or sale.

Key Details

• Transaction date: June 12, 2026; Form 4 filed June 15, 2026.
• Grant: 50,000 stock options, exercise price $0.94 each (equal to MIRA’s closing price on 6/12/2026 per the filing).
• Vesting: 50% vests at the six-month anniversary of the grant; remaining 50% vests at the 12‑month anniversary.
• Post-transaction holdings: Not specified in the provided excerpt of the filing.
• Filing timeliness: Form shows filing on 6/15/2026 for a 6/12/2026 grant; no explicit late-filing flag provided in the summary.

Context

• This was a grant of options (award), not an exercise or sale. The options give the holder the right to buy shares at $0.94 each once vested; exercising would require payment of the strike price (50,000 × $0.94 = $47,000) and is a separate action.
• Option grants to directors are commonly part of compensation and do not by themselves indicate buying or selling sentiment.